2023
Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration
Rein S, Lodi S, Logan R, Touloumi G, Antoniadou A, Wittkop L, Bonnet F, van Sighem A, van der Valk M, Reiss P, Klein M, Young J, Jarrin I, Monforte A, Tavelli A, Meyer L, Tran L, Gill M, Lang R, Surial B, Haas A, Justice A, Rentsch C, Phillips A, Sabin C, Miro J, Trickey A, Ingle S, Sterne J, Hernán M, Collaboration A. Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration. The Lancet HIV 2023, 10: e723-e732. PMID: 37923486, PMCID: PMC10695103, DOI: 10.1016/s2352-3018(23)00233-3.Peer-Reviewed Original ResearchConceptsART-experienced individualsCardiovascular eventsTarget trialsART regimensRisk ratioTreatment strategiesRisk differenceEligibility criteriaIntegrase strand transfer inhibitor useAntiretroviral Therapy Cohort CollaborationIntegrase strand transfer inhibitorsPooled logistic modelART-naive individualsHIV RNA measurementsHIV-CAUSAL CollaborationNational InstituteStrand transfer inhibitorsLogistic regression modelsART regimenCohort CollaborationAntiretroviral therapyInhibitor useBlood pressureINSTI useClinical data
2022
Predicting counterfactual risks under hypothetical treatment strategies: an application to HIV
Dickerman BA, Dahabreh IJ, Cantos KV, Logan RW, Lodi S, Rentsch CT, Justice AC, Hernán MA. Predicting counterfactual risks under hypothetical treatment strategies: an application to HIV. European Journal Of Epidemiology 2022, 37: 367-376. PMID: 35190946, PMCID: PMC9189026, DOI: 10.1007/s10654-022-00855-8.Peer-Reviewed Original Research